$1.6 Billion is the total value of Novo Holdings A/S's 48 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BSX | Sell | BOSTON SCIENTIFIC CORP | $62,607,058 | -8.3% | 1,353,081 | -23.2% | 3.91% | +20.1% |
| AAPL | Sell | APPLE INC | $47,957,683 | -24.8% | 369,104 | -20.0% | 2.99% | -1.5% |
| Sell | ARCELLX, INC. | $45,974,940 | -23.3% | 1,484,020 | -53.5% | 2.87% | +0.5% | |
| PCVX | Sell | VAXCYTE INC | $34,763,750 | +75.8% | 725,000 | -12.0% | 2.17% | +130.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $25,590,939 | +16.7% | 2,095,900 | -0.2% | 1.60% | +52.9% |
| ALGS | Exit | ALIGOS THERAPEUTICS INC | $0 | – | -1,950,000 | -100.0% | -0.10% | – |
| SPNE | Exit | SEASPINE HLDGS CORP | $0 | – | -525,867 | -100.0% | -0.14% | – |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -3,703,991 | -100.0% | -0.26% | – |
| NKTX | Exit | NKARTA INC | $0 | – | -823,200 | -100.0% | -0.52% | – |
| Exit | MINERVA SURGICAL INC | $0 | – | -1,862,877 | -100.0% | -0.82% | – | |
| MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -2,000,000 | -100.0% | -0.88% | – |
| VTI | Exit | VANGUARD INDEX FDStotal stk mkt | $0 | – | -1,525,550 | -100.0% | -23.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.